Neutralization of IL-6 decreases AG and vessel stabilization at 1 week. (A) Quantification of Matrigel tube formation assay after 24 hours in the presence of mock secretome (Mock scr), mock secretome with a nonrelated antibody (Mock scr + nrAb), mock secretome with anti–IL-6, anti–GM-CSF, and anti–IL-8/CXCL8 (Mock scr + αAbs), HCMV VR1814 secretome (VR1814 scr), HCMV VR1814 secretome with a nonrelated antibody (VR1814 scr + nrAb), HCMV VR1814 secretome with anti–IL-6 antibody (VR1814 scr + αIL-6), HCMV VR1814 secretome with anti–GM-CSF antibody (VR1814 scr + αGM-CSF), HCMV VR1814 secretome with anti–IL-8/CXCL8 antibody (VR1814 scr + αIL-8), and HCMV VR1814 secretome with anti–IL-6, anti–GM-CSF, and anti–IL-8/CXCL8 antibodies (VR1814 scr + αAbs). The results are expressed as mean ± SD, ^###P < .001 versus mock, **P < .01 versus HCMV VR1814 secretome. (B) Representative examples of each culture conditions are shown as a low-power image (magnification, ×10). (C) Tubule survival is shown after 1 week on Matrigel in the presence of mock secretome, HCMV VR1814 secretome, HCMV VR1814 secretome with anti–IL-6 antibody (VR1814 scr + αIL-6) at low-power image (magnification, ×10), and at high-power image (magnification, ×20).